HRTX Heron Therapeutics Inc.

14.80
-0.40  -3%
Previous Close 15.20
Open 15.30
Price To book 11.56
Market Cap 801253248
Shares 54,138,733
Volume 359,831
Short Ratio 27.97
Av. Daily Volume 685,729

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released August 2016. Phase 3 trial initiated with completion due 1H 2018.
HTX-011
Bunionectomy and hernia repair
CRL Mar 28 2013. Approved August 10 2016.
APF530 - Sustol
Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)
PDUFA date November 12, 2017.
CINVANTI (HTX-019)
Prevention of chemotherapy-induced nausea and vomiting (CINV)

Latest News

  1. Heron Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
  2. Heron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : September 14, 2017
  3. Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : September 12, 2017
  4. What Does Heron Therapeutics Inc’s (HRTX) Share Price Indicate?
  5. Heron Therapeutics Shows Rising Relative Strength; Still Shy Of Key Threshold
  6. Heron Therapeutics Shows Rising Price Performance With Jump To 82 RS Rating
  7. Heron Therapeutics Trying To Close In On Key Technical Benchmark
  8. Should You Buy Heron Therapeutics (HRTX) Ahead of Earnings
  9. Heron Therapeutics reports 2Q loss
  10. Heron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress
  11. Heron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA
  12. ETFs with exposure to Heron Therapeutics, Inc. : July 24, 2017
  13. Heron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : July 7, 2017
  14. Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : July 6, 2017
  15. Heron Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HRTX-US : June 20, 2017
  16. Heron Therapeutics to Present at the Jefferies 2017 Healthcare Conference
  17. Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : May 29, 2017
  18. Heron Therapeutics, Inc. – Value Analysis (NASDAQ:HRTX) : May 12, 2017